Bausch + Lomb: Positive Results for Premium LuxSmart ™ Intraocular Lenses, After One Year of Real World Experience | Business

MONTPELLIER, France – (BUSINESS WIRE) – October 7, 2021–

Bausch + Lomb, a leading global eye health company of Bausch Health Companies Inc. (NYSE / TSX: BHC), today announced positive results following the field assessment of ‘one year of its high-end LuxSmart ™ glass, since its European launch in 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005489/en/

Now adopted by 200 surgeons in 18 countries, LuxSmart ™ is designed to provide continuous distance vision to the intermediary.

More than 5,000 cataract patients have now been treated worldwide, including more than 4,000 in Europe. 1 LuxSmart ™ is a hydrophobic lens, designed with Pure Refractive Optics (PRO) technology, suitable for patients with certain co-morbidities and could be used to obtain near vision through micromonovision.

Mr Mayank Nanavaty, ophthalmic consultant at Nuffield Health Brighton Hospital UK, explains: “My patients increasingly favor intermediate and far vision, as modern life now takes place mainly at arm’s length via laptops, iPad and electronic books. So when I was asked to try LuxSmart ™, I was very interested. The design meets all of my major demands: it’s non-diffractive, spherical aberration based, hydrophobic, and as a bonus, it’s preloaded. “

He added, “I have used it in my cataract patients with great results and the patient feedback has been phenomenal. LuxSmart ™ is distinguished from other lenses by its wider continuous range of high quality far and intermediate vision which can be achieved without glare or halos. I have also found that about 30% of my patients also acquire near vision, which allows them to read the fine print without glasses.

Evaluation in patients with bilateral cataracts indicates that LuxSmart ™ performs extremely well at distance (BCDVA, -0.03 logMAR) and intermediate (DCIVA at 80 and 66 cm, mean 0.07 and 0.14 logMAR, respectively) . The DCNVA at 40 cm reached 0.38 logMAR during the treatment of bilateral cataracts. 1

Prof. Michael Koss, FEBO, ophthalmologist at Eye Center Nymphenburger Höfe Munich, Germany, is a regular user: “So far the results have exceeded my expectations. Through the use of LuxSmart ™, my patients achieved optimal intermediate vision with excellent distance vision. Additionally, none of my patients reported dysphotopsia. I am excited about the potential of this lens and what it offers my clinic and my patients.

LuxSmart ™ is fully preloaded across the entire diopter range and is available as a toric. LuxSmart ™ is part of the Lux intraocular lens (IOL) platform from Bausch + Lomb which includes LuxGood ™, a monofocal IOL. The platform is available with and without violet light filtering, clear and yellow options and is based on a four-point attachment haptic designed to achieve lens centering, rotational stability and greater predictability of the refraction.

1.8 billion people worldwide are expected to have presbyopia by 2050, including 280 million in Europe. Presbyopia generally begins around 40 to 45 years old. 2

For more information on LuxSmart ™, please visit www.LuxSmartIOL.com.

About LuxSmart ™

LuxSmart ™ is a premium IOL with a pure refractive optics (PRO) design. An increased field of vision is created by a central area designed with the combination of the 4th and 6th orders of spherical aberration of opposite signs. Rather than creating one (monofocal) or multiple separate focal points (multifocal), this design provides a wider continuous range of functional vision, from distance to intermediate. LuxSmart ™ is a one-piece, hydrophobic, biconvex acrylic IOL with a four point attachment and a 360º square edge design.

About Bausch + Lomb

Bausch + Lomb, one of the leading global eye health companies of Bausch Health Companies Inc., is all about helping people see better, live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the industry’s most comprehensive product portfolios, available in approximately 100 countries. For more information, visit www.bauschsurgical.eu.

###

® / TM are registered trademarks of Bausch & Lomb Incorporated or its affiliates.

All other product names / brands and / or logos are trademarks of their respective owners.

© 2021 Bausch & Lomb Incorporated or its affiliates.

1 Bausch + Lomb sales data, August 2021

2 Grzybowski, Andrzej MD, PhD, MBA ∗; Markeviciute, Agne MD †; Zemaitiene, Reda MD, PhD † A review of the pharmacological treatment of presbyopia, Asia-Pacific Journal of Ophthalmology: May-June 2020 – Volume 9 – Issue 3 – p 226-233 doi: 10.1097 / APO.00000000000000297.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211007005489/en/

CONTACT: Media:

Nick Massey / Claire Reid

Nick @ mearnsandpike.com / Claire @ mearnsandpike.com

+44 7557 769884 / +49 176 24597452

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: MEDICAL DEVICES FOR OPTICAL HEALTH SURGERY

SOURCE: Bausch + Lomb

Copyright Business Wire 2021.

PUB: 07/10/2021 05:51 / DISC: 07/10/2021 05:52

http://www.businesswire.com/news/home/20211007005489/en

Source link

About Marion Alexander

Check Also

Pathway Eye celebrates its 20th anniversary | Local News

Pathway Eye announced its 20th anniversary as a full-service optometry practice, with locations in Athens, …

Leave a Reply

Your email address will not be published. Required fields are marked *